TP方案化疗序贯三维适形放疗在食管癌治疗中应用.docVIP

TP方案化疗序贯三维适形放疗在食管癌治疗中应用 薛志东 泰州市人民医院肿瘤科，江苏泰州225300 The application about sequential chemotherapy with Taxol plus Cisplatin(TP) and three dimensional conformal radiation therapy in esophageal cancer XUE Zhi-dong Department of Oncology ，People’s Hospital of Taizhou City，Taihou 225300，P.R.China 【摘　要目的TP方案化疗序贯三维适形放疗在食管癌治疗中疗效及不良反应。方法：76例符合标准的食管癌患者，随机分为治疗组和对照组。治疗组先予TP方案化疗四周期，后行三维适形放射治疗；对照组单用三维适形放射治疗。结果：76例患者均可进行评价。疗效:治疗组有效率（RR）为92.1%；对照组RR为81.6%；两组间RR比较无统计学差异（P＞0.05）1、2、3年生存率：治疗组为81.6%、60.5%和36.8%；对照组为71.1%、50.0%和28.9%；两组生存曲线比较无统计学差异（P＞0.05）。两组不良反应主要有白细胞减少、放射性食管炎、放射性肺炎和恶心呕吐等；治疗组3～4级白细胞减少发生率为84.2%，对照组为10.5%，两组间比较有统计学差异（P＜0.05）；余不良反应两组间比较无统计学差异（P＞0.05）。结论：TP方案化疗序贯三维适形放疗治疗食管癌安全有效，值得进一步扩大样本研究。 [ABSTRACT] OBJECTIVE:To observe the effectiveness and adverse reaction about sequential chemotherapy with Taxol plus Cisplatin(TP) and three dimensional conformal radiation therapy(3DCRT) in esophageal cancer. METHODS: 76 patients with esophageal cancer enrolled in this study were equally randomized into two groups : the research group with 38 patients who were given sequentially 4 cycles of chemotherapy (TP) and radiotherapy (3DCRT), the control group with 38 patients who were given radiotherapy (3DCRT) only. RESULTS: All 76 cases were evaluable for objective response. Though the complete and partial remission rate (CR+PR) was 92.1％ in the research group and 81.6% in the control group（P＞0.05） The median survival was 28 months in the research group and 24 months in the control group. The 1 -, 2-and 3-year overall survival rate was 81.6% , 61.5% , 36. 8% in the research group, versus 71.1%, 50. 0%, 28.9% in the control group（P＞0.05）any adverse reactions were observed in the research group and the control group such as WBC decrease, Radiation esophagitis, Radiation pneumonitis, Nausea and Vomiting etc , nevertheless two groups were no significant difference（P＞0.05）xcluding 3 to 4 WBC decrease’s incidence rate was 84.2％ in the research group and .5% in the control gr